One Wealth Management Investment & Advisory Services LLC Buys 17 Shares of Eli Lilly and Company (NYSE:LLY)

One Wealth Management Investment & Advisory Services LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 817 shares of the company’s stock after buying an additional 17 shares during the quarter. One Wealth Management Investment & Advisory Services LLC’s holdings in Eli Lilly and Company were worth $740,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in LLY. Tidemark LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock traded down $10.04 during trading on Friday, hitting $902.71. The stock had a trading volume of 3,439,999 shares, compared to its average volume of 3,063,074. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company’s 50-day moving average price is $895.97 and its two-hundred day moving average price is $827.49. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $857.94 billion, a P/E ratio of 132.95, a PEG ratio of 2.91 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LLY shares. Truist Financial restated a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, August 19th. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 75,510 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $860.78, for a total transaction of $64,997,497.80. Following the transaction, the insider now owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 737,410 shares of company stock worth $669,719,100 in the last ninety days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.